The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with a PD-1 inhibitor.

The present disclosure provides materials and methods for cell-free expression of epitopes for immunotherapy applications. In particular, the present disclosure provides materials and methods for expressing concatenated epitopes using a cell-free protein synthesis platform for high throughput, large scale, and unbiased epitope screening and the generation of multi-epitope vaccines.

Embodiments concern methods and composition for preventing or treating a bacterial infection, particularly infection by a Staphylococcus bacterium. The embodiments concern improved non-toxigenic Protein A (SpA) variant.

Embodiments concern methods and composition for preventing or treating a bacterial infection, particularly infection by a Staphylococcus bacterium. The embodiments concern improved non-toxigenic Protein A (SpA) variant.

The current invention relates to the treatment of cancer. In particular the invention relates to modulating the anti-tumor immunity in a cancer patient. The disclosed invention is in particular useful in the treatment of so-called cold tumors and/or in tumors that are resistant to or acquired resistance to treatment with immune checkpoint modulators. Compounds for use in the disclosed treatment, combinations and methods of treatment are provided.

The current invention relates to the treatment of cancer. In particular the invention relates to modulating the anti-tumor immunity in a cancer patient. The disclosed invention is in particular useful in the treatment of so-called cold tumors and/or in tumors that are resistant to or acquired resistance to treatment with immune checkpoint modulators. Compounds for use in the disclosed treatment, combinations and methods of treatment are provided.

A method of forming an immunomodulatory implant operatively arranged to chemotactically facilitate bone morphogenesis, the method including forming a matrix of a first material, the matrix including an outer surface, and a plurality of pores, and applying an antigen to the matrix, wherein the antigen including at least one of a bacterial antigen or a viral antigen.

A method of forming an immunomodulatory implant operatively arranged to chemotactically facilitate bone morphogenesis, the method including forming a matrix of a first material, the matrix including an outer surface, and a plurality of pores, and applying an antigen to the matrix, wherein the antigen including at least one of a bacterial antigen or a viral antigen.

A detoxified Staphylococcal Exotoxin B (SEB) toxin that is mutated to comprise at least two point mutations at amino acid positions 21 to 25 in the SEB toxin sequence SEQ ID NO:1, wherein said at least two point mutations comprise a deletion of any of aa21-22, aa22-23, aa23-24, aa24-25, aa21-23, aa22-24, or aa23-25, or at corresponding amino acid positions in any other naturally-occurring SEB toxin sequence that has at least 95% sequence identity to SEQ ID NO:1.

A detoxified Staphylococcal Exotoxin B (SEB) toxin that is mutated to comprise at least two point mutations at amino acid positions 21 to 25 in the SEB toxin sequence SEQ ID NO:1, wherein said at least two point mutations comprise a deletion of any of aa21-22, aa22-23, aa23-24, aa24-25, aa21-23, aa22-24, or aa23-25, or at corresponding amino acid positions in any other naturally-occurring SEB toxin sequence that has at least 95% sequence identity to SEQ ID NO:1.